AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34237987 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatments (non-surgical group)
Number of subjects: 40
Study 32867832 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy ‐ Toddler
Number of subjects: 90
Study 32867832 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security‐ Parenting™
Number of subjects: 90
Study 32867832 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study 35316689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 128
Study 35316689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 34975132 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 100
Study 34975132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36399194 — intervention group
Group type: EXPERIMENTAL
Intervention: LDAC plus nintedanib
Number of subjects: 30
Study 36399194 — intervention group
Group type: COMPARATOR
Intervention: LDAC plus placebo
Number of subjects: 30
Study 36399194 — intervention group
Group type: EXPERIMENTAL
Intervention: LDAC plus nintedanib (in r/r AML)
Number of subjects: 30
Study 36399194 — intervention group
Group type: COMPARATOR
Intervention: LDAC plus placebo (in r/r AML)
Number of subjects: 30
Study 32556730 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoblock (15 ml retromuscularly and 15 ml subcutaneously)
Number of subjects: 66
Study 32556730 — intervention group
Group type: COMPARATOR
Intervention: Control (no Haemoblock)
Number of subjects: 66
Study 32556730 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoblock
Number of subjects: 66
Study 32556730 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 32654395 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CPT delivery
Number of subjects: 30
Study 32654395 — intervention group
Group type: EXPERIMENTAL
Intervention: F2F CPT delivery
Number of subjects: 30
Study 32654395 — intervention group
Group type: COMPARATOR
Intervention: Control (no program)
Number of subjects: 30
Study 35518935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone dose of 0.2-0.3 mg/kg/day
Number of subjects: 52
Study 35518935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone dose of 0.4-0.6 mg/kg/day
Number of subjects: 52
Study 32385676 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kit
Number of subjects: 272
Study 35785344 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital integrated care using the migraine app M-sense combined with a communication platform (online consultations and medically moderated patient forum)
Number of subjects: 0
Study 35785344 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33539713 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation app task (app-task)
Number of subjects: 12
Study 33539713 — intervention group
Group type: COMPARATOR
Intervention: Map task
Number of subjects: 12
Study 33539713 — intervention group
Group type: COMPARATOR
Intervention: Photo-language task
Number of subjects: 12
Study 33028263 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 0
Study 33028263 — intervention group
Group type: COMPARATOR
Intervention: Anxiety disorders
Number of subjects: 0
Study 33028263 — intervention group
Group type: COMPARATOR
Intervention: Anorexia nervosa (AN)
Number of subjects: 0
Study 34546554 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QoL questionnaire
Number of subjects: 283
Study 34546554 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L utility score
Number of subjects: 283
Study 34546554 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAD model 4 (total IBS-QoL score and squared IBS-SSS)
Number of subjects: 283
Study 34546554 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QoL and EQ-5D-5L
Number of subjects: 283
Study 34732432 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (62 patients)
Number of subjects: 506
Study 34732432 — intervention group
Group type: COMPARATOR
Intervention: Non-anticoagulation treatment (446 patients)
Number of subjects: 506
Study 34732432 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (506 patients)
Number of subjects: 506
Study 34732432 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anticoagulation therapy
Number of subjects: 506
Study 35189937 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) consisting of 14 teleconference sessions with the child and parents, supported by an app for symptom assessment and wristband monitoring.
Number of subjects: 60
Study 35189937 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group receiving treatment after a 16-week waiting period.
Number of subjects: 60
Study 34076179 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 34
Study 34076179 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% oral glucose
Number of subjects: 34
Study 34076179 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% oral glucose combined with non-nutritive sucking
Number of subjects: 34
Study 32614037 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown marmorated stink bug adults and nymphs feeding (1.7‐4.0 feeding sites per fruit)
Number of subjects: 6
Study 32614037 — intervention group
Group type: COMPARATOR
Intervention: Control (no brown marmorated stink bug)
Number of subjects: 6
Study 33499714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 66
Study 33499714 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 66
Study 33499714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine and Topiramate
Number of subjects: 66
Study 34111902 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Adaptive Block Randomization (RABR) design
Number of subjects: 0
Study 33207841 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐figure shoulder brace
Number of subjects: 33
Study 33207841 — intervention group
Group type: COMPARATOR
Intervention: No shoulder brace (control)
Number of subjects: 33
Study 34196852 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation of oral cavity for 3 min before operation
Number of subjects: 24
Study 34196852 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate irrigation of oral cavity for 3 min before operation
Number of subjects: 24
Study 33512412 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with involved-field radiation therapy (RT)
Number of subjects: 1711
Study 33512412 — intervention group
Group type: COMPARATOR
Intervention: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide without involved-field radiation therapy (RT)
Number of subjects: 1711
Study 33512412 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional chemotherapy with dexamethasone, etoposide, cisplatin, and cytarabine for patients with slow early response
Number of subjects: 1711
Study 32779096 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 50 U
Number of subjects: 61
Study 32779096 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 25 U
Number of subjects: 61
Study 32779096 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study 34990581 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER) 60 mg/reduced 30 mg
Number of subjects: 21105
Study 34990581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (LDER) 30 mg/reduced 15 mg
Number of subjects: 21105
Study 34990581 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 35221703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine (standard dose)
Number of subjects: 110
Study 35221703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (standard dose)
Number of subjects: 110
Study 35221703 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (standard dose)
Number of subjects: 110
Study 35221703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine (up-dosing)
Number of subjects: 110
Study 35221703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (up-dosing)
Number of subjects: 110
Study 35221703 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine + Hydroxyzine (combination)
Number of subjects: 110
Study 35962371 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game-based cognitive training (CCT)
Number of subjects: 162
Study 35962371 — intervention group
Group type: COMPARATOR
Intervention: Passive wait list control
Number of subjects: 162
Study 35962371 — intervention group
Group type: COMPARATOR
Intervention: Active control (watching documentaries)
Number of subjects: 162
Study 33954789 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid (ZA) with calcium and vitamin D; 5 infusions (0.025 mg/kg at months 0 and 3, 0.05 mg/kg at months 6, 12, and 18)
Number of subjects: 62
Study 33954789 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D alone (Control)
Number of subjects: 62
Study 32548775 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 0
Study 32548775 — intervention group
Group type: COMPARATOR
Intervention: Immediate multivessel PCI
Number of subjects: 0
Study 33921063 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 2286
Study 33980185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium supplementation
Number of subjects: 0
Study 33980185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36358447 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 12 weeks
Number of subjects: 0
Study 36358447 — intervention group
Group type: COMPARATOR
Intervention: Conventional detoxification
Number of subjects: 0
Study 34970330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized glucocorticoid
Number of subjects: 145
Study 34970330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized glucocorticoid combined with bronchodilator
Number of subjects: 145
Study 34970330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 145
Study 34970330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 145
Study 35849397 — intervention group
Group type: EXPERIMENTAL
Intervention: RealRisks decision aid for patients and the Breast Cancer Risk Navigation Tool decision support for clinicians
Number of subjects: 187
Study 35849397 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 187
Study 33293362 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis
Number of subjects: 262
Study 33293362 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 262
Study 36278221 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-O2 group (inhaled H2-O2 mixture 66% H2/33% O2)
Number of subjects: 60
Study 36278221 — intervention group
Group type: COMPARATOR
Intervention: Air group (inhaled placebo air)
Number of subjects: 60
Study 34431518 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 326
Study 34431518 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 326
Study 34431518 — intervention group
Group type: COMPARATOR
Intervention: EWL ?5%
Number of subjects: 326
Study 34431518 — intervention group
Group type: COMPARATOR
Intervention: EWL <5%
Number of subjects: 326
Study 33567701 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (Lactica-seibacillus paracasei strain Shirota and Bifidobacterium breve strain Yakult, and galactooligosaccharides) for 24 weeks
Number of subjects: 88
Study 33567701 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 88
Study 33567701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 36226902 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 0
Study 36226902 — intervention group
Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 0
Study 32188366 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000IU vitamin D3 per week
Number of subjects: 27
Study 32188366 — intervention group
Group type: EXPERIMENTAL
Intervention: 80,000IU vitamin D3 per week
Number of subjects: 27
Study 32188366 — intervention group
Group type: EXPERIMENTAL
Intervention: 110,000IU vitamin D3 per week
Number of subjects: 27
Study 32062731 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 1852
Study 32062731 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 1852
Study 32062731 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (in cervical adenocarcinoma or adenosquamous carcinoma)
Number of subjects: 1852
Study 32062731 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (in cervical adenocarcinoma or adenosquamous carcinoma)
Number of subjects: 1852
Study 36334697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D administration
Number of subjects: 216
Study 36334697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 33522881 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU triage policies that promote population health outcomes and mitigate health inequities.
Number of subjects: 0
Study 32046418 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose secnidazole 2 g
Number of subjects: 0
Study 32046418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34055971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on predictive variables (age, site, grade, tumor size, histology, stage, use of surgery, radiotherapy, or chemotherapy)
Number of subjects: 813
Study 35705975 — intervention group
Group type: EXPERIMENTAL
Intervention: iSTART web-app intervention
Number of subjects: 600
Study 35705975 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 600
Study 35705975 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 600
Study 33106479 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal genetic risk score (GRS) associated with offspring birthweight
Number of subjects: 26057
Study 33106479 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring genetic risk score (GRS)
Number of subjects: 26057
Study 33394543 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1745
Study 33394543 — intervention group
Group type: COMPARATOR
Intervention: Non-metformin users
Number of subjects: 1745
Study 32032356 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme based on the ICF framework
Number of subjects: 203
Study 32032356 — intervention group
Group type: COMPARATOR
Intervention: Short talk and a booklet on interprofessional practice (control)
Number of subjects: 203
Study 36320143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose temsirolimus (0.1 mg/mL)
Number of subjects: 61
Study 36320143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose temsirolimus (0.4 mg/mL)
Number of subjects: 61
Study 36320143 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 61
Study 36320143 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (combined low and high dose)
Number of subjects: 61
Study 36320143 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 61
Study 34173042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroschisis (girls)
Number of subjects: 328
Study 34173042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroschisis (boys)
Number of subjects: 328
Study 34173042 — intervention group
Group type: EXPERIMENTAL
Intervention: Omphalocele
Number of subjects: 328
Study 32723109 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 G × 4 mm pen needle (PN)
Number of subjects: 209
Study 32723109 — intervention group
Group type: COMPARATOR
Intervention: Thinner comparator pen needles (33–34 G × 3.5–4 mm PNs and one 34 G × 4 mm PN)
Number of subjects: 209
Study 35643358 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein peptide (TMP, n = 15)
Number of subjects: 47
Study 35643358 — intervention group
Group type: COMPARATOR
Intervention: Casein (TMC, n = 16)
Number of subjects: 47
Study 35643358 — intervention group
Group type: COMPARATOR
Intervention: Indigestible dextrin (TMF, n = 16)
Number of subjects: 47
Study 32212254 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation combined with virtual reality (VR) training (15 min, two times a day for 5 days)
Number of subjects: 152
Study 32212254 — intervention group
Group type: COMPARATOR
Intervention: Early rehabilitation alone
Number of subjects: 152
Study 32212254 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation combined with virtual reality (VR) training
Number of subjects: 152
Study 36004439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lighting installation
Number of subjects: 54
Study 34624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin cement (RelyX Ultimate) with universal adhesive (Scotchbond Universal) without selective enamel etching (SB-E)
Number of subjects: 50
Study 34624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin cement (RelyX Ultimate) with universal adhesive (Scotchbond Universal) with selective enamel etching (SB+E)
Number of subjects: 50
Study 34624421 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive resin cement (RelyX Unicem 2; RXU)
Number of subjects: 50
Study 34601619 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration-adsorption (CPFA)
Number of subjects: 115
Study 34601619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 33262767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHS (spontaneous clearance)
Number of subjects: 86
Study 33262767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHC (chronic infection)
Number of subjects: 86
Study 33262767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHC
Number of subjects: 86
Study 33262767 — intervention group
Group type: COMPARATOR
Intervention: Patients
Number of subjects: 86
Study 35470243 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐POEM
Number of subjects: 41
Study 35470243 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 41
Study 34688948 — intervention group
Group type: COMPARATOR
Intervention: T-cell receptor beta chain (TCRβ) features in COVID-19 patients
Number of subjects: 0
Study 34688948 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic model based on TCRβ clones
Number of subjects: 0
Study 33638879 — intervention group
Group type: COMPARATOR
Intervention: Continuous Aerobic Exercise Training (CAET)
Number of subjects: 47
Study 33638879 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 47
Study 33638879 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 47
Study 36401364 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich gel (APRG)
Number of subjects: 72
Study 36401364 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 72
Study 33598778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid gel + open flap debridement (OFD)
Number of subjects: 20
Study 33598778 — intervention group
Group type: COMPARATOR
Intervention: open flap debridement (OFD) + placebo
Number of subjects: 20
Study 32176093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES) treatment on 3 consecutive days in addition to best supportive care
Number of subjects: 400
Study 32176093 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment on 3 consecutive days in addition to best supportive care
Number of subjects: 400
Study 34382725 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU patients
Number of subjects: 523
Study 33453044 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and Behavioral Health‐Crisis Response and Prevention (EBH‐CRP) intervention
Number of subjects: 40
Study 33174935 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 0
Study 33174935 — intervention group
Group type: COMPARATOR
Intervention: Clinical-case-based discussion
Number of subjects: 0
Study 33174935 — intervention group
Group type: COMPARATOR
Intervention: Online tutorial
Number of subjects: 0
Study 34524009 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric continuous glucose monitoring (CGM)
Number of subjects: 64
Study 34524009 — intervention group
Group type: COMPARATOR
Intervention: Traditional point-of-care (POC) glucose testing + blinded CGM
Number of subjects: 64
Study 32585837 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate + bioactives (WPI + BIO) capsules containing omega‐3 fatty acids, rutin, and curcumin
Number of subjects: 37
Study 32585837 — intervention group
Group type: COMPARATOR
Intervention: Whey protein isolate (WPI)
Number of subjects: 37
Study 32585837 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate + placebo capsules (CHO)
Number of subjects: 37
Study 32585837 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate + bioactives (WPI + BIO)
Number of subjects: 37
Study 35624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder engagement process including community meetings and qualitative interviews with new fathers
Number of subjects: 16
Study 35624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Advisory Board and qualitative interviews
Number of subjects: 16
Study 35624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of fathers and community leaders
Number of subjects: 16
Study 34585449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepidium meyenii (yellow maca)
Number of subjects: 50
Study 34585449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50